Many surface markers, including CD106 (Vcam1), CD51 (Itgav) and CD61 (Itgb3), are heterogeneously expressed in the mesenchymal YFP+ EpCAM– population of tumor cells in more than 75% of tested tumors. This evidence concerns the gene VCAM1 and neoplasm.